Mycophenolate(my coe fen’ oh late)
Mycophenolate Mofetil
CellCept
Mycophenolate Sodium
MyforticDNC
PREGNANCY CATEGORY D
Drug class
Immunosuppressant
Therapeutic Actions
Immunosuppressant: Inhibits T-lymphocyte activation; exact mechanism of action unknown, but binds to intracellular protein, which may prevent the generation of nuclear factor of activated T cells, and suppresses the immune activation and response of T cells; inhibits proliferative responses of T and B cells.
Indications
Prophylaxis of organ rejection in patients receiving allogeneic renal, hepatic, and heart transplants; intended to be used concomitantly with corticosteroids and cyclosporine; Myfortic used for renal transplants only
Unlabeled uses: Refractory uveitis as 2 g/day alone or in combination therapy; second-line agent for Churg-Strauss syndrome; combined with prednisolone for diffuse proliferative lupus nephritis
Contraindications and Cautions
Contraindicated with allergy to mycophenolate, pregnancy, lactation.
Use cautiously with impaired renal function.
Available Forms
Capsules—250 mg; tablets—500 mg; DR tabletsDNC—180, 360 mg (Myfortic); powder for oral suspension—200 mg/mL; powder for injection—500 mg/vial
Dosages
Adults
Renal transplantation: 1 g bid PO or IV (administered over at least 2 hr) starting as soon as possible after transplant; 720 mg PO bid on an empty stomach (Myfortic).
Cardiac transplantation: 1.5 g PO bid or IV (IV over at least 2 hr).
Hepatic transplantation: l g IV bid (over at least 2 hr) or 1.5 g PO bid.
Pediatric patients
Renal transplantation: 600 mg/m2 oral suspension PO bid (up to a maximum daily dose of 2 g/10 mL oral suspension); 400 mg/m2 PO bid to a maximum 720 mg bid (Myfortic).
Geriatric patients
Maximum recommended dose is 720 mg PO bid (DR tablets) (Myfortic).
Patients with severe renal or hepatic impairment
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
